Skip to main content
OpenTrials
Completed

NCT Number: NCT04501822

One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia

The primary objective of the study is to assess the cardiac status of COVID-19 pneumonia patients during 1 year after discharge

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Cardiac Complication Cardiovascular Diseases Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science

Tyumen, 625026, Russia

About this study

Although COVID-19 manifests in most cases with respiratory symptoms, cardiovascular abnormalities is common in hospitalized patients. Patients with cardiovascular risk factors or established disease appear to have a worse prognosis. Myocardial dysfunction could be a direct manifestation of COVID-19. The investigators hypothesize that subjects after COVID-19 pneumonia present myocardial and vascular remodeling during 1 year after discharge, even in the absence of prior cardiovascular disease.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-Patients with documented COVID-19 pneumonia

Exclusion criteria

  • Patients with cancer
  • Impossible to follow up

Treatment and study plan

Evaluation of clinical, instrumental and laboratory diagnostics tests

Diagnostic Test

During follow-up visits patients undergo clinical, instrumental and laboratory diagnostics tests

Primary outcomes

  1. Echocardiographic assessment of cardiac function

    Time frame: up to one year

    Echocardiographic assessment of global strain parameters at 3 and 12 months after discharge

Secondary outcomes

  1. МАССЕ

    Time frame: up to one year

    Major adverse cardiac and cerebrovascular events: cardiac death, myocardial infarction, or stroke at 3 and 12 months after discharge

  2. Quantitative analysis of parenchymal lung damage

    Time frame: up to one year

    Describe the parenchymal lung damage through a quantitative analysis with chest CT at 3 and 12 months after discharge

  3. Functional exercises capacity assessment

    Time frame: up to one year

    Six-min walk test at 3 and 12 months after discharge

  4. Evaluation of renal function

    Time frame: up to one year

    Measure of creatinine clearance at 3 and 12 months after discharge

  5. Evaluation of inflammation

    Time frame: up to one year

    Analysis for C-reactive protein at 3 and 12 months after discharge

  6. Evaluation of coagulation abnormality

    Time frame: up to one year

    Analysis for activated clotting time at 3 and 12 months

  7. Evaluation of quality of life in first year after discharge

    Time frame: up to one year

    Assessment of the Short Form Health Survey (SF36) at 3 and 12 months after discharge

Sponsors and collaborators

Lead sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Other

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Aug 6, 2020
Registry last updated
Jun 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.